Replace Therapeutics

Acquired By Tome Biosciences
CRISPR-based genome editing platform is developed for genetic diseases.

About Replace Therapeutics

Replace Therapeutics is a Healthcare company, and was acquired by Tome Biosciences in January 2024. CRISPR-based genome editing platform is developed for genetic diseases. Its chief executive, as recorded, is Shakked Halperin. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms.

Company details

A CRISPR-based genome editing platform is being developed by Replace Therapeutics for treating genetic diseases. Programmable genomic integration technology is utilized, combining the site-specificity of CRISPR and Cas9 with the DNA ligase enzyme to enable precise manipulation of small DNA sequences. Operations focus on biotechnology within the healthcare sector, with leadership provided by CEO Shakked Halperin.

Key Metrics

Investors in Replace Therapeutics

Replace Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Tome Biosciences.

All
InvestorDescriptionFounded YearDomainLocation
CRISPR-based gene insertion platform for genomic medicines is developed.
2021tome.bioCambridge, United States
Premium access

Investor details for Replace Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Replace Therapeutics

1 people are tracked at Replace Therapeutics (1 in leadership).

NameRoleGroup
Shakked Halperin
CEOLeadership
Premium access

Complete people profiles for Replace Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Replace Therapeutics

Shakked Halperin is the CEO of Replace Therapeutics, as recorded in our data.

A CRISPR-based genome editing platform is being developed by Replace Therapeutics for treating genetic diseases. Programmable genomic integration technology is utilized, combining the site-specificity of CRISPR and Cas9 with the DNA ligase enzyme to enable precise manipulation of small DNA sequences. Operations focus on biotechnology within the healthcare sector, with leadership provided by CEO Shakked Halperin.

Replace Therapeutics has 1 investor. Key investors include Tome Biosciences.

Yes. Replace Therapeutics was acquired by Tome Biosciences in January 2024.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available